Continued uncertainty about the Federal Reserve's tapering schedule weighed the markets down to a lower close with the Dow plummeting 104 points to 15,739. Nasdaq lost 5 points to 3998.
On the upside
MarketWatch noted that the Food and Drug Adminstration's director of Drug Evaluation and Research, Janet Woodcock, made comments that implied support of Sarepta Therapeutics' (Nasdaq: SRPT) experimental Duchenne muscular dystrophy treatment eteplirsen.
Medicare contractor CGS will begin reimbursing MiMedx Group (Nasdaq: MDXG) for its wound care allograft EpiFix.
Twitter (NYSE: TWTR) introduced introduced a new mobile advertising program.
On the downside
GeoInvesting questioned the accounting practices of AmTrust Financial Services (Nasdaq: AFSI).
Investors locked in profits on BG Medicine (Nasdaq: BGMD).
Violin Memory (NYSE: ANR) chief technical officer Jonathan Goldrick resigned and rumors circulated that chief executive officer Don Basille may soon depart.
In the broad market, declining issues outpaced advancers by a margin of more than 7 to 5 on the NYSE and by nearly 10 to 9 on Nasdaq. The broader S&P 500 fell 6 points to 1775. Bitcoin edged up $2.83 or 0.32% to $897.00.
